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The eye is the commonest site for non-cutaneous melanomas,
accounting for approximately 80% of such lesions (Scotto et al,
1976). Ocular melanomas principally arise from the uveal tract,
which comprises the iris, ciliary body and the choroid, the highest
incidences are for the posterior (ciliary body and choroid)
melanomas, with an annual frequency, in America, of 5–7 cases
per million population (Egan et al, 1988; Rennie, 1991). A genetic
predisposition has been suggested to be amongst the predisposing
risk factors for this disease, with at least 40 families showing
increased susceptibility (Canning and Hungerford, 1988; Singh
et al, 1996), and recent evidence has implied that a relationship
may exist with breast cancer (Wooster et al, 1995).
The cytogenetic alterations of the majority of solid malignan-
cies are poorly understood, with solid tumours comprising approx-
imately 27% of all reported cytogenetic analyses and, of these, less
than 1% relate to melanomas (Mitelman, 1994). Posterior uveal
melanomas are relatively atypical amongst adult solid tumours,
because they are highly amenable to chromosome analysis and
often possess only minimal cytogenetic alterations (Prescher et al,
1990, 1995; Sisley et al, 1990, 1992; Horsman and White, 1993;
Wiltshire et al, 1993; Singh et al, 1994). This propensity has
permitted the identification of consistent anomalies of chromo-
somes 3, 6 and 8; in particular, loss of chromosome 3 is associated
with alterations of chromosome 8, principally in the form of an
isochromosome 8q, and such abnormalities appear to be correlated
with those tumours with a ciliary body component (Sisley et al,
1990, 1992; Prescher et al, 1992, 1996; Dahlenfors et al, 1993;
Horsman and White, 1993; Singh et al, 1994). Ciliary body
melanomas are known to have an adverse prognosis (McLean
et al, 1977), and the close association of chromosomes 3 and 8
with this phenotype has led to the suggestion, and confirmation,
that the presence of such chromosome alterations identify uveal
melanoma patients with significantly reduced survival (Prescher
et al, 1996; Sisley et al, 1997). Although uveal melanomas do not
usually demonstrate high levels of chromosome aberrations, alter-
ations of other chromosomes, such as those of chromosomes 1, 11,
21 and the Y chromosome, also occur with a reasonable consis-
tency (Prescher et al, 1990, 1995; Sisley et al, 1990, 1992;
Horsman and White, 1993; Gordon et al, 1994; Singh et al, 1994;
Speicher et al, 1994); but it is unclear whether these changes asso-
ciate with specific stages of tumour development, or with tumour
sub-groups. In this report, we examined the specific involvement
of individual chromosomes in a series of 42 primary uveal
melanomas. Patients were referred with previously untreated uveal
melanomas, during an 8-year period, to a national centre based at
the department of Ophthalmology and Orthoptics, Sheffield
University. Cytogenetic analysis of some patients had been
reported formerly (Sisley et al, 1990, 1992; Tappin et al, 1996),
and the significance of chromosomes 3 and 8 changes already
documented (Sisley et al, 1997).
MATERIALS AND METHODS
Clinical details
Informed patient consent and ethical approval were obtained prior
to commencing the study. A series of 42 formally untreated
patients with posterior uveal melanomas (ciliary body and
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choroid) were examined during the period 1987–1995. The
majority of patients were treated by enucleation (removal of the
eye), although six patients underwent local resection of the
primary tumour. The cohort consisted of 29 males and 13 females,
ranging in age from 43 to 90 years (median 66 years). Estimation
of tumour size was conducted preoperatively by B scan ultra-
sonography (Cooper Vision), and the longest tumour diameter in
contact with the sclera was determined (Ltd). All melanomas were
categorized histopathologically according to the AFIP system of
classification for uveal melanoma (Spencer, 1986). The clinico-
pathological details of the previously unreported patients are
presented in Table 1.
Cytogenetic analysis
Uveal melanoma biopsies were processed immediately upon
resection as previously reported (Sisley et al, 1990, 1997). Tumour
cultures were continually assessed, and when sufficient growth
had been procured, cells were harvested and chromosome prepara-
tions made and banded (Sisley et al, 1990), with abnormalities
recorded in accordance with international guidelines (ISCN,
1991).
Statistical analysis
Statistical association was assessed by constructing 2´2 contin-
gency tables of the variables. Statistical significance was
evaluated using Pearson c2 and Fishers’ Exact test with a P-value
of < 0.05 taken to indicate significance.
RESULTS
Cytogenetic analysis and the clinical and histopathological details
of 18 patients has been reported previously. Cases Som 10, 11, 17,
22, 30 and 35 were presented in Sisley et al (1990), cases Som 36,
37, 47, 52, 53, 57, 59, 60, 61, 62 and 63, were detailed in Sisley et
al (1992) and cases Som 95 and 140 reported in Tappin et al
(1996). The significance of chromosome 3 and 8 abnormalities in
the series of 42 patients has been considered separately (Sisley
et al, 1997). Cytogenetic analysis from the uveal melanomas is
detailed in Table 2 and the clinicopathological details are
presented in Table 1.
The results of cytogenetic analysis for all 42 cases was exam-
ined. The incidence for involvement of individual chromosomes in
numerical and structural changes was ascertained as a percentage
of tumours possessing such abnormalities (results not shown). In a
given tumour, if aneuploidy of both homologues was present, or if
both experienced structural rearrangements, the occurrence was
only recorded once. From the study the commonest chromosome
abnormalities were confirmed to be loss of chromosome 3 (21
tumours, 50% of melanomas) and the Y chromosome (16 tumours,
38% of melanomas), and structural alterations of chromosomes 1,
6 and 8 (13, 16 and 21 tumours representing 30%, 38% and 50% of
melanomas respectively). The distribution of breakpoints for
structural alterations in the series was determined (Figure 1), and
although most chromosomes experienced some rearrangement, the
occurrence of breakpoints was not random. Chromosome 8 was
the most heavily implicated in structural rearrangements, with
breakpoints concentrated at the centromeric region, whilst both
arms of chromosome 6 were equally represented. Breakpoints on
chromosome 1 were predominantly at the centromeric region, and,
in common with other breakpoints on chromosome 1p, produced
an effectual deletion of the short arm, often as a result of unbal-
anced translocations (Figure 2). Also of interest was the apparent
hotspot at chromosome 11q23 (Figure 1).
To associate chromosome abnormalities with phenotypic
features, the incidence of numerical and structural alterations was
determined in relation to tumour location, size and cell type
(Figures 3 and 4). The significance of the specific changes of chro-
mosomes 3 (loss) and 8 has been previously recounted (Sisley et
al, 1997), and will not be considered in this report. Structural alter-
ations of chromosome 6 (p and q) were found in both ciliary body
(8/24 tumours) and choroid melanomas (8/18 tumours) (P = 0.46).
Trisomy of chromosome 21 occurred more frequently in ciliary
body melanomas (6/24) although this did not achieve statistical
significance (P = 0.23). Similarly, chromosome 1 p deletions were
found predominantly in ciliary body melanomas (11/24); this was
statistically significant (P = 0.016). Abnormalities of chromosome
Table 1 Clinicopathological details of the patients
Case no Sex Tumour location and cell Diameter and
volume
type in (mm)
Som 10 Male Choroid (C), Spindle cell (S) 12.45/929.53
Som 11 Female Cilary Body (CB), Mixed cell 11.1/1352.75
(M)
Som 14 Male C, M 15.25/769.37
Som 17 Male C, M 13.5/1025.83
Som 22 Male Cilary body/choroid (CB/C), M 12.7/1419.15
Som 27 Male C, Epithelioid (E) 11.8/769.64
Som 30 Male CB/C –
Som 35 Male CB, E 12/398.13
Som 37 Female CB/C, M –
Som 40 Female C, M 11/590.97
Som 42 Male C, M 15.1/2043.15
Som 44 Female CB/C, M 15.3/1518.99
Som 47 Male C, M 13.25/466 30
Som 52 Female CB/C, M 17.45/1664.67
Som 53 Male CB/C, M 15.6/2897.72
Som 57 Female CB/C, M 14.7/2226.14
Som 59 Male C, M 17.1/2282.73
Som 60 Male C, M 9.55/825.28
Som 61 Male C, M 13.45/962.84
Som 62 Male CB/C, E 18.05/2168.57
Som 63 Male C, S 16.3/723.1198
Som 95 Male CB/C, M 21.75/3939.70
Som 96 Female CB, M 16.8/3292.50
Som 98 Male C, S 12.05/1349.02
Som 99 Female CB, S 12/387.81
Som 100 Female CB, E 13.5/1172.09
Som 112 Male CB/C, S 19/2605.95
Som 113 Male CB/C, M 19.65/2918.02
Som 115 Male CB, E 10.8/500.22
Som 118 Male C, S 16.4/1477.20
Som 119 Male C, M 24/4041.91
Som 120 Male CB, M 6.3/392.77
Som 122 Male CB, M 12.65/1492.11
Som 124 Male CB/C, S 22.2/5241.26
Som 125 Female C, M 19.1/2239.61
Som 126 Male CB/C, M 16.75/2937.64
Som 128 Female C, S 15.45/2478.55
Som 134 Male C, S 10.3/756.65
Som 135 Male CB, M 19.4/1657.42
Som 136 Male C, S 11.3/530.60
Som 137 Female CB/M 16.2/1580.36
Som 140 Female CB/S 13.6/1836.91332 K Sisley et al
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11 occurred more frequently in choroidal tumours, again this failed
to achieve statistical significance (P = 0.10).
From comparison of the cytogenetic changes with increasing
tumour size, it was observed that an increase in tumour size,
whether in the diameter, thickness or volume, was associated with
an increase in the number of chromosomes partaking in numerical
changes (Figure 4A). Tumours greater than 15 mm in diameter
possessed approximately three times the numbers of total
numerical abnormalities compared with those of less than 15 mm
diameter, although a corresponding increase for structural
alterations was not observed (Figure 4B). When individual homo-
logues were considered, abnormalities of chromosomes 1, 3, 6, 8,
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Figure 1 Idiogram showing distribution of breakpoints for structural alterations in the series. l denotes a tumour with a breakpoint in this region, l denotes
five tumours with breakpoints n denotes a tumour with a possible breakpoint in this region.Cytogenetics of uveal melanoma 333
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9, 10, 17 and Y were found to be more common in the larger
tumours (Figure 4), although involvement was not significant for
any chromosome (P = 0.31, P = 0.18, P = 0.50, P = 0.37, P =
0.053, P = 0.07, P = 0.15 and P = 0.51 respectively). No specific
trends for chromosome abnormalities could be related to cell type
(data not shown).
DISCUSSION
The association of chromosomes 3, 6 and 8 changes with posterior
uveal melanoma has been clearly documented (Prescher et al,
1990, 1995; Sisley et al, 1990, 1992; Dahlenfors et al, 1993;
Horsman and White, 1993; Wiltshire et al, 1993; Singh et al,
1994). Equally well recognized is the relationship between chro-
mosome 6 and cutaneous melanoma (Ray et al, 1996), and the
observation that similar alterations of chromosome 6 occur in
uveal melanoma (Prescher et al, 1990, 1995; Sisley et al, 1990;
Horsman and White, 1993; Wiltshire et al, 1993; Singh et al,
1994). It is unclear as to which chromosome changes may be
considered to be related to a general pathology of cell type, such as
neural crest derivation, or even melanoma associated changes, and
what changes, if any, depict differences in those melanomas
arising in sites other than the skin. Indeed recent evidence suggests
that amongst uveal melanomas (ciliary body, choroid and iris)
those melanomas arising in the iris have cytogenetic abnormalities
different to those of the posterior uvea (White et al, 1995; Sisley et
al, 1998), and as iris melanomas are by comparison relatively
benign (Sunba et al, 1980), it is possible that these differences may
account for variations in aggressive behaviour.
It is of interest that as the tumour enlarges there is a demon-
strable increase in the numerical changes, whilst structural alter-
ations show no such pattern. Greater aneuploidy may either be
representative of specific essential changes associated with tumour
progression, or, with the exception of chromosome 3 loss, indicate
unrelated ‘background noise’ illustrative of the presumably
advanced nature of these tumours (Johansson et al, 1996).
Cytogenetic abnormalities can be segregated into balanced and
unbalanced aberrations, according to their ultimate effect on the
genetic constitution (Johansson et al, 1996). Under this model
balanced structural abnormalities, such as translocations or inver-
sions, result in gene rearrangements and can be considered as
primary, whereas numerical changes, trisomies and monosomies,
produce gross genetic imbalances and would be considered
secondary (Johansson et al, 1996). In uveal melanoma most alter-
ations yield unbalanced rearrangements and would therefore fall
into the category of secondary, possibly unrelated changes
(Johansson et al, 1996). It is also important to consider the poten-
tial implications of the mechanics behind these abnormalities.
Numerical changes may simply arise as the by-product of poorly
regulated cell division, comparable to the increased genetic insta-
bility associated with p53 or BUB1 mutant cells (Agapova et al,
1996; Cahill et al, 1998), and therefore occur more frequently in
the larger uveal melanomas as a result of other, perhaps unde-
tected, genetic abnormalities. Structural alterations require DNA
breakage and reunion, and in uveal melanoma they occur without
particular regard to increasing tumour size, with the possible
exceptions of rearrangements of chromosomes 9 and 10 which are
found in cutaneous and some uveal melanomas (Magauran et al,
1994; Healy et al, 1995; Ohta et al, 1996). It is possible that struc-
tural abnormalities could conceivably represent a more specific
mechanism than for most numerical changes; regardless of
whether they transpire to be primary or secondary aberrations.
In uveal melanoma certain alterations, particularly those of
chromosomes 3 and 8, are known to be more common in tumours
arising from select locations (Sisley et al, 1990, 1992; Prescher et
al, 1992, 1996; Dahlenfors et al, 1993; Horsman and White, 1993;
Singh et al, 1994), and the results of this study, in combination
with previous cytogenetic analysis, would suggest that this classi-
fication can be extended to include other alterations. In ciliary
body melanomas, or those of a mixed location, structural abnor-
malities of chromosomes 1 and 8, and aneuploidy of chromosomes
3 and 21, are more frequently observed (Sisley et al, 1990, 1992;
Dahlenfors et al, 1993; Horsman and White, 1993; Wiltshire et al,
1993; Singh et al, 1994; Prescher et al, 1995). In choroid
melanomas, or again those of a mixed location, rearrangements of
chromosomes 6 and 11 are more likely (Sisley et al, 1990,  1992;
Dahlenfors et al, 1993; Horsman and White, 1993; Singh et al,
1994; Prescher et al, 1995). An interesting paradox can be seen
when observing mixed ciliary body/choroid melanomas, as they
appear to combine chromosome aberrations from both localities.
In these mixed melanomas abnormalities of chromosomes 1, 3, 6,
8, 11 and 21 are all found, although at the other extremes, changes
of chromosomes 1, 3, 8 and 21 are infrequent amongst those
melanomas entirely derived from the choroid, whilst equally rare
are rearrangements of chromosomes 6 and 11 in purely ciliary
body-derived melanomas. It is unclear why these mixed
melanomas possess abnormalities of both locations, but it is
possible that environmental factors may play a role. This associa-
tion with tumour location may explain why chromosome alter-
ations are predictive of survival. Ciliary body melanomas have a
worse prognosis (McLean et al, 1977), and recent evidence
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Figure 2 Unbalanced translocations affecting chromosome 1, producing
effectual deletions of the short arm. Abnormal chromosomes are indicated by
arrowheads. (A) Case Som 11, der(15)t(1;15)(q11;p13), first reported in
Sisley et al (1990); (B) Case Som 112, der(15)t(1;15)(q11;p13); (C) case
Som 113, der(1)t(1;8)(q10;q10); (D) case Som 115, der(13)t(1;13)(q11;p13);
(E) case Som 120, der(13)t(1;13)(q11;p13); (F) case Som 137,
der(22)t(1;22)(q11;p11)334 K Sisley et al
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suggests that abnormalities of chromosomes 3 and 8 identify a
poor outcome, whilst those of chromosome 6, more common in
choroid melanomas, are a good prognostic indicator (Prescher et
al, 1996; Sisley et al, 1997; White et al, 1998). At least in terms of
their cytogenetic alterations it would appear that these two
melanomas have different genetic backgrounds, leading to
speculation that in some way the locality itself dictates the genetic
changes required for the tumour to progress, a suggestion perhaps
compounded by the observation that the relatively benign iris
melanomas have different changes (White et al, 1995; Sisley et al,
1998).
Through comparison of tumour enlargement with chromosome
changes, it is apparent that certain aberrations become more
frequent as the tumour progresses, including those of chromo-
somes 1, 3, 6, 8, 11 and Y, already identified as non-randomly
involved. In addition trisomy of chromosome 21 and structural
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Figure 3 The percentage of tumours with numerical (A) and structural (B) alterations of individual chromosomes related to tumour location. C = choroid
melanomas, CB = ciliary body melanomas, CB/C = mixed site melanomas. (A) The loss of a chromosome is shown below the line, and the gain of a
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alterations of chromosomes 9, 10 and 17 also occur (Figure 4).
Deletions of chromosomes 9, 10 and 17 are found in cutaneous
melanomas (Healy et al, 1995), and uveal melanomas have also
been shown to have loss of regions on chromosome 9 (Magauran
et al, 1994; Ohta et al, 1996). As changes of chromosomes 1, 3, 8
and 21 are more common to melanomas with a ciliary body
component (Figure 3), and because of their progressive acquisi-
tion, the sequence of cytogenetic alterations for ciliary body
melanomas could be proposed as, monosomy chromosome 3
(Prescher et al, 1994), followed by additional 8q (often as an
isochromosome), which is subject to amplification (Sisley et al,
1997), possibly accompanied at some later point by deletions of
chromosome 1p and/or trisomy 21. In choroid melanomas the
situation is less apparent, although the common involvement of
chromosomes 6 and 11 alterations would suggest they may play a
role. Since chromosome 6 rearrangements were detected in more
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Figure 4 The involvement of chromosomes in relation to increasing tumour size. (A) The percentage of tumours with numerical changes in tumours of above
(> 15 mm) and below (< 15 mm) 15 mm diameter; (B) the percentage of tumours with structural alterations when compared to tumour diameter336 K Sisley et al
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Table 2 Cytogenetic analysis of the tumours from patients with primary posterior uveal melanoma
Case Karyotype
no
Som 10 7 Cells 46, XY
4 Cells 46,XY,der(11)t(6;11)(p21;p15)
Som 11 6 Cells 44,XX,–1,–3,+i(8)(q10),–14,der(15)t(1;15)(q11;p13)
4 Cells 44,XX,–1,–3,+i(8)(q10),–14,der(15)t(1;15)(q11;p13),del(20),(q11)
2 Cells 45,XX,–1,–3,+i(8)(q10),–14,der(15)t(1;15)(q11;p13), del(20)(q11),+mar
Som 14 4 Cells 46,X,–Y,der(15)t(6;15)(p12;q22),+mar,inc
Som 17 11 Cells 46,XY
Som 22 8 Cells 46,X,–Y,del(1)(p12p32),+7,add(22)(p13),add(22)(p13)
5 Cells 46,X,–Y,del(1)(p12p32),add(6)(q22),+7,add(22)(P13),add(22)(P13)
Som 27 4 Cells 47,XX,–3,+add(8)(p11),del(11)(q23),+mar,inc
Som 30 8 Cells 44,XY,–3,–6,i(8)(q10),+i(8)(q10),der(9)t(6;9)(p12;q21),–17
5 Cells 43,XY,–3,–6,i(8)(q10),+i(8)(q10),der(9)t(6;9)(p12;q21),–16,–17
Som 35 4 Cells 46,X,–Y,–3,i(6)(p10),+7,i(8)(q10),+i(8)(q10),–16,+21
3 Cells 47,X,–Y,–3,i(6)(p10),+7,i(8)(q10),+i(8)(q10),+21,del(22)(q11)
5 Cells 46,X,–Y,–3,i(6p),+7,i(8)(q10),der(8;12)(q10;q10),+21
Som 37 14 Cells 46,XX,
2 Cells 46,XX,–3,i(6)(p10),i(8)(q10),+i(8)(q10)
Som 40 4 Cells 47,X,–X,add(8)p12),+2mar,inc
Som 42 5 Cells 46,XY,del(6)(q14q15),add(17)(p12q24),+mar,inc
Som 44 3 Cells 45,XX,–3,del(6)(q?24q?25),+i(8)(q10),–17,inc
Som 47 27 Cells 46,XY,der(6)t(6;6)(q27;p12),del(11)(q23),add(12)(q24),add(14)(q32),
add(18)(q23),add(19)(q13),add(22))(q13)
Som 52 11 Cells 46,XX,t(1;10)(p13;q24),–3,i(8)(q10),+i(8)(q10),del(11)(q23)
9 Cells 46,XX,t(1;10)(p13;q24),–3,+i(8)(q10),del(11)(q23)
6 Cells 45,XX,t(1;10)(p13;q24),–3,+i(8)(q10),del(11)(q23)
Som 53 17 Cells 44,XY,–3,add(6)(q13–14),–9,der(17)t(9;17)(q10;q10)
5 Cells 43,XY,–3,add(6)(q13–14),–9,–13,der(17)t(9;17)(q10;q10)
4 Cells 44,XY,–3,add(6)(q13–14),–9,–13,der(17)t(9;17)(q10;q10)+mar
Som 57 14 Cells 46,XX
3 Cells 45,XX,–3,i(8)(q10)
Som 59 10 Cells 49,XY,+8,der(13)t(6;13)(p12;q34),+der(13)t(6;13)(p12;q34),+21
8 Cells 45,X,–Y
4 Cells 46,XY,der(13)t(6;13)(p12;q34)
3 Cells 46,XY
2 Cells 47,X,–Y,+6,+22
Som 60 13 Cells 46,XY
6 Cells 45,X,–Y
Som 61 9 Cells 46,XY
Som 62 10 Cells 45,X,–Y,–3,+8
4 Cells 45,X,–Y,–3,+8,del(11)(q13q13)
4 Cells 45,X,–Y,–3,+i(8)(q10),del(11)(q13q13)
Som 63 14 Cells 46,XY
5 Cells 46,XY,del(6)(q21q21)
4 Cells 46,XY,del(6)(q21q21),del(7)(q11q11)
3 Cells 47,XY,+5,del(6)(q21q21),del(7)(q11q11)
3 Cells 45,X,–Y
2 Cells 48,XY,+4,+5,del(6)(q21q21),del(7)(q11q11)
2 Cells 46,XY,–6,del(6)(q21q21),+10
Som 95 6 Cells 44,X,–Y,der(1)t(1;8)(q10;q10),–3
Som 96 6 Cells 46,XX
3 cells 72<3n>,XXX,–1,+2,–3,+6,+7,+8,+11,+12,–15,+16,–18,–19,+20
Som 98 5 cells 45,X,–Y,del(11)(q23),inc
Som 99 2 cells 46,XX
Som 100 2 cells 46,XX
Som 112 7 cells 46,X,–Y–1,–3,+i(8)(q10),der(15)t(1;15)(q11;p13),+20,+21
4 cells 47,X,–Y,i(1)(q10),–3,+8,+21,+22
3 cells 48,X,–Y,–3,+8,+20,+21,+mar
3 cells 45,X,–Y,–1,–3,+i(8)(q10),der(15)t(1;15)(q11;p13),+21
2 cells 48,X,–Y,–3,+i(8)(q10),der(15)t(1;15)(q11;p13),+20,+21,+mar
Som 113 10 cells 44,X,–Y,der(1)t(1;8)(q10;q10),–3
2 cells 45,X,–Y,der(1)t(1;8)(q10;q10),–3,+21
3 cells 44,X,–Y,der(1)t(1;8)(q10;q10),–3,del(11)(q?)
Som 115 5 cells 46,XY,–1,–3,del(6)(q?16q?22),+i(8)(q10),+i(8)(q10),
der(13)t(1;13)(q11;p13),add(20)(p12)
Som 118 30 cells 46–54,X,–Y,+2[2],der(3)t(1;3)(q23;p24–25)[7],+4[4],–6[30],+7[3],
+8[3],add(9)(q34)[11],add(9)(p12)[5],–10[10],add(10)(p12)[12],
del(11)(q23)[3],+12[3],add(12)(p?)[2],+15[4],add(16)(q24)[8],
+18[17],del(18)(p?)[5],add(19)(q13)[30],+21[3], +22[3],
+1–5mar[cp30]Cytogenetics of uveal melanoma 337
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melanomas, it may be reasonable to expect that such changes
occur prior to those of chromosome 11, of which breakpoints at, or
around, 11q23 appear to be particularly implicated.
In uveal melanoma there is a remarkable consistency for
reported structural aberrations (Prescher et al, 1990, 1995; Sisley
et al, 1990, 1992; Dahlenfors et al, 1993; Horsman and White,
1993; Wiltshire et al, 1993; Singh et al, 1994), which in some
instances includes both the selection of translocation partners and
the location of breakpoints (Figures 1 and 2). In this study the
frequent structural rearrangements of chromosome 1 are particu-
larly interesting in this respect. These exchanges appear to be non-
random yielding consistent genetic imbalances (deletions of 1p),
perhaps important to the development, in particular the progres-
sion, of mainly ciliary body melanomas. Similar changes are also a
common event in cutaneous melanomas, possibly associated with
tumour progression, and several genes have been implicated
(Dracopoli et al, 1989). In posterior uveal melanoma there appears
to be a surprising affinity for certain translocation partners of chro-
mosome 1 (Figure 2) particularly amongst the D Group, with
reported cases detailing repeated involvement of chromosomes 8,
13, and 15 in comparable translocations with the same, or similar,
breakpoints implicated (Prescher et al, 1990; Sisley et al, 1990,
1992; Horsman and White, 1993; Tappin et al, 1996). This
reproducibility suggests an underlying mechanism in which
regions containing highly repetitive DNA sequences are strategi-
cally implicated. An analogous situation is perhaps found in breast
cancer, where a reproducible translocation affecting chromosomes
1 and 16 has been observed (Kokalj-Vokac et al, 1993). The break-
points were found to span the heterochromatic regions, with the
significant event considered to be the ensuing imbalance (Kokalj-
Vokac et al, 1993). In posterior uveal melanoma in addition to the
net imbalance, the preferential affiliation for repetitive sequences,
without a prerequisite for pairing with the same homologue, may
suggest other motives, perhaps related to deficiencies in DNA
repair (Surralles et al, 1997). Whether this selection is essential or
coincidental awaits disclosure.
Cytogenetic analysis of posterior uveal melanoma appears to
provide valuable insights into the necessary genetic alterations
related to its development and progression. This study would
suggest that in addition to changes of chromosome 3 and 8, alter-
ations of chromosomes 1 and 21 correlate with ciliary body
melanomas, whereas in choroid melanomas abnormalities of chro-
mosomes 6 and 11 are more frequent. It is also of interest that
structural rearrangements of chromosome 1 appear to associate
with tumour progression and in particular the consistency of
breakpoints involved in these alterations may help to identify the
underlying genes responsible for such behaviour.
Table 2 Continued
Case Karyotype
no
Som 119 5 cells 45,X,–Y
Som 120 3 cells 44,X,–Y,–1,–3,+i(8)(q10),der(13)t(1;13)(q11;p13)
4 cells 46,X,–Y,–1,–3,+i(8)(q10)´3,der(13)t(1;13)(q11;p13)
3 cells 94<4n>,XX,–Y,–Y,–1,–1,–3,–3,+i(8)(q10)´6,der(13)t(1;13)(q11;p13)´2,
+21,+21
Som 122 16 cells 44–45,X,–Y,[16],–3[16],i(8)(q10)[2],i(8)(q10),+i(8)(q10)[3],i(8)(q10),
+i(8)(q10)´2[5],+i(8)(q10)´2[3],+i(8)(q10)´3[3],–13[6],
add(13)(p11)[7],–16[12][cp16]
Som 124 10 cells 46,XY,del(1)(p?),add(6)(q21–25),add(9)(q34),
der(10)(t(8;10)(q11;p13),der(18)t(6;18)(p21;q23)
Som 125 6 cells 48,X,–X,del(1)(p36),+del(1)(p36),–3,i(8)(q10),+i(8)(q10)´2,
+der(8)t(8;8)(p23;q23)
4 cells 48,X,–X,del(1)(p36),+del(1)(p36),–3,i(8)(q10),+i(8)(q10)´2,
+der(8)t(8;8)(p23;q23),i(17)(q10)
Som 126 10 cells 46,XY
Som 128 20 cells 46,XX,der(6)t(6;8)(q16;q13),der(11)t(6;11)(p21;q23),
add(11)(p15),der(20)t(6;20)(p11;p11)
Som 134 8 cells 45,X,–Y
2 cells 46,XY
Som 135 7 Cells 73–75<3n>,X,–X[7],–X[7],del(2)(q?)[3],–3[7],+4[7],+5[7],+6[2],+7[4],
i(8)(q10)[7],+i(8)(q10)[7],+13[2],+14[2],–15[2],–16[5],
+19[2],–20[3],+20[2],+21[5],+22[4][cp7]
Som 136 9 Cells 46,XY
5 Cells 46,XY,del(2)(q22),add(5)(p?),del(6)(q?),add(16)(q?),add(17)(q?),
add(19)(p?)
2 Cells 46,XY,del(2)(q22),add(5)(p?),del(6)(q?),add(16)(q?),add(17)(q?),
add(19)(p?),del(21)(q?)
Som 137 2 Cells 44,X,-X,–1,–3,i(8)(q10),der(8)t(8;8)(p22;q21),del17(q21q22),
der(19)t(9;19)(q13;p13),der(22)t(1;22)(q11;p11),+1mar
11 Cells 45,X,-X,–1,–3,i(8)(q10),der(8)t(8;8)(p22;q21),del17(q21q22),
der(19)t(9;19)(q13;p13),+21,der(22)t(1;22)(q11;p11),+1mar
2 Cells 44,X,-X,–1–3,i(8)(q10),der(8)t(8;8)(p22;q21),–10,del17(q21q22),
der(19)t(9;19)(q13;p13),+21,der(22)t(1;22)(q11;p11),+1mar
Som 140 4 Cells 44–46,X,-X[14],add(1)(p31)[5],–3[14],+8[14],add(16)(q21)[7],
+mar1[5],+mar2[4][cp14]338 K Sisley et al
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